Efficacy of Bendamustine in treating Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Efficacy of Bendamustine in treating Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Description:

– PowerPoint PPT presentation

Number of Views:4
Slides: 18
Provided by: Username withheld or not provided
Category:
Tags:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Efficacy of Bendamustine in treating Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia


1
Efficacy of Bendamustine in Treating
Non-Hodgkin Lymphoma and Chronic Lymphocytic
Leukemia
2
Bendamustine hydrochloride is a cytotoxic
anti-cancer medication approved by the FDA for
the treatment of first line chronic lymphocytic
leukemia and relapsed non-Hodgkin Lymphoma. It
works by interfering with the cell replication by
the double stranded DNA and cross linking single
DNA.  
3
Bendamustine (Brand Treanda) is an alkylating
agent whose structure bears similarities to
chlorambucil, cyclophosphamide and other
medications from the class of nitrogen mustard.
It is also similar to a benzimidazole ring
which acts as an antagonist to amino acid and
purines. Bendamustine / Treanda Cost Information
4
Bendamustine Mechanism of Action Chronic
lymphocytic Leukemia Chronic Lymphocytic
Leukemia is the most commonly diagnosed form of
leukemia in North America and Europe. It is
estimated that there are more than 15,600 new
cases of CLL diagnosed every year. It is also
estimated that the causality rate from CLL is
over 4500 deaths annually.
5
The 5 year survival year of CLL patients is
estimated to be approximately 82. In the
clinical courses of patients with CLL, it was
found that some patients experienced rapid
progression of the disease while others survival
time improved without requiring treatment
6
As of March of 2008, Bendamustine hydrochloride
(Brand Treanda) was approved for the treatment of
Chronic Lymphocytic Leukemia. For this
approval, the FDA reviewed the efficacy of
Bendamustine vs chlorambucil as first-line
treatment for previously untreated patients with
advanced CLL on the basis of randomized parallel
groups, open label multi-centre trials.
7
The patients were assigned to be treated with
either 100 mg / m2 injection IV of bendamustine
on day 1 2 for every 4 weeks or 0.8 mg / kg
oral of chlorambucil on day 1 15 for every 4
week treatment cycle. The patients were
assigned these medications on a random basis for
accurate results. This treatment cycle was
repeated 6 times for every patient. A majority of
patients in either groups had immunophenotypic
confirmation of CLL.
8
The overall response rate in patients treated
with bendamustine was higher when compared to
patients treated with chlorambucil. The median
PFS (time from randomization of assigning
patients to progression or death from any cause)
was found to be 18 months for bendamustine and 6
months for chlorambucil.
9
Bendamustine Mechanism of Action non-Hodgkin
Leukemia Non-Hodgkin Lymphoma or NHL is a type
of cancer that forms in the white blood cells
known as lymphocytes which are a part of the
immune system. NHL is more commonly diagnosed
that other types of lymphoma. Different
sub-types of NHL also exist like diffuse large
B-cell lymphoma or follicular lymphoma. Early
diagnosis and treatment of NHL may improve
prognosis for the patients.
10
As of October 31st of 2008, Bendamustine
hydrochloride (Brand Treanda) was approved for
the treatment of indolent B-cell NHL. For this
approval, the FDA reviewed the efficacy of
Bendamustine through the results of a hundred
patients who were treated with rituximab. The
19 patients included from this study had relapsed
within 6 months of receiving the first dose or
the last dose of rituximab.
11
Those patients were treated with 60-120 minutes
of 120 mg / m2 of bendamustine injection IV on
day 1 2 for every 3 weeks treatment cycle.
This treatment cycle was repeated up to 8 times
for every patient. About 2/3 of the patients had
the advanced stage of NHL at the time of the
enrolment in the trial. The overall response
rate in patients treated with bendamustine was
74. Single agents bendamustine was founded to
more durable responses that lasted for median of
9.2 months.
12
  • Bendamustine / Treanda side effects
  • Some Bendamustine side effects include
  • Liver Problems, Signs
  • Pain In Upper Stomach
  • Loss Of Appetite
  • Dark Urine
  • Clay-colored Stools 
  • Jaundice
  • Itchiness
  • Tiredness
  • Coughing

13
  • Chest Pains And/Or Difficulty In Breathing
  • Pain Or A Burning Sensation While Urinating
  • Continuing Nausea
  • Diarrhoea And/Or Vomiting Itchiness
  • Chills And/Or Fever During Or After Receiving An
    Injection Low Blood Cell Count
  • Signs Skin Sores
  • Mouth Sores
  • Easy Bruising
  • Unusual Bleeding

14
  • Pale Skin And/Or Fever
  • Tumour Cell Breakdown,
  • Signs Fluttering In Chest,
  • Faster Or Slower Heartbeat,
  • Confusion,
  • Tingling In Hands,
  • Feet Mouth,
  • Vomiting And/Or Diarrhoea

15
  • Some of The More Common Side Effects Include
  • Loss Of Appetite And Weight Loss
  • Skin Rash That Is Mild
  • Swelling In Hands And Feet
  • Tiredness, Dizziness And/Or Headaches
  • Vomiting, Nausea, Constipation And/Or Diarrhoea
  • Coughing, Mouth Sores
  • Fever
  • Trouble Breathing

16
Bendamustine Cost Information The information
provided on the page is meant for the purpose of
being helpful and educational. It should not be
considered as medical advice.     bendamustine,
treanda, bendamustine side effects, bendamustine
rituximab, bendamustine cost, bendamustine
mechanism of action, treanda cost, bendamustine
hydrochloride, treanda side effects, bendamustine
injection
17
Contact Us Website www.CancerCurePharmacy.com E
mail CustomerCare_at_CancerCurePharmacy.com
About PowerShow.com